TORONTO, July 1, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), a cannabis company with core operations in Latin
America, applauds the EU-Mercosur Trade Agreement announced
between the European Union and Mercosur, the Latin American trading
block made up of Argentina,
Brazil, Uruguay and Paraguay. Khiron is active among Mercosur
jurisdictions with a recently completed acquisition of NettaGrowth
International, a cannabis company based in Uruguay.
The trade deal between the European Union and Mercosur announced
on June 28, 2019 at the G20 Summit in
Japan, which is subject to
ratification by member countries, establishes a trade framework for
goods and services, including pharma and medical products, covering
nearly 780 million consumers, making it the largest in the world in
terms of population, and with an estimated trade in goods of
88 Billion Euros (Source: European
Commission).
Alvaro Torres, Khiron CEO and
Director, comments "As we build Khiron's dominant position in
Latin America and Mercosur markets
through our operations in Uruguay,
we welcome this trade deal as it strengthens our ability to now
directly supply the European medical cannabis market. This
significant milestone is another step towards a globalized medical
cannabis trade network where Latin
America, with its strategic location, many natural
advantages and regulatory leadership, will continue to play a
significant part."
Khiron announced completion of the acquisition of NettaGrowth
International on June 19, 2019.
NettaGrowth, and its wholly-owned subsidiary Dormul S.A. is a
Uruguayan company that has obtained one of the first licences to
produce and export medical cannabis with THC for commercialization
in Uruguay, and is positioned to
serve Brazil and the growing Latin
American market as part of the Mercosur trading block, adopting the
Company's scalable model as markets develop.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in the
country for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented approach,
the Company combines global scientific expertise, agricultural
advantages, branded product market entrance experience and
education to drive prescription and brand loyalty to address
priority medical conditions such as chronic pain, epilepsy,
depression and anxiety in the Latin American market of over 620
million people. Khiron is led by Co-founder and Chief Executive
Officer, Alvaro Torres, together
with an experienced executive team, and a knowledgeable Board of
Directors that includes former President of Mexico, Vicente
Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
To be added to the distribution list, please email:
khiron@kcsa.com with "Khiron" in the subject line.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Forward-looking statements may be identified by
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Forward-looking
statements herein include, but are not limited to, statements
regarding the anticipated benefits of the acquisition, Dormul's
cultivation capacity, receipt by Dormul of an extraction licence,
and receipt of all required regulatory approvals, including final
approval of the TSXV, among others. Readers are cautioned to not
place undue reliance on forward-looking information. Actual results
and developments may differ materially from those contemplated by
these statements. Khiron undertakes no obligation to comment
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-welcomes-eu-trade-deal-with-latin-american-countries-300878338.html
SOURCE Khiron Life Sciences Corp.